Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.
2.

Variation in BRCA1 cancer risks by mutation position.

Thompson D, Easton D; Breast Cancer Linkage Consortium..

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):329-36.

3.

BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.

Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, Pharoah PD.

Breast Cancer Res. 2002;4(1):R2.

4.

Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.

Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé MP, Kieback DG, Narod SA.

Pharmacogenetics. 2001 Oct;11(7):635-8.

PMID:
11668223
5.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A.

J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23.

PMID:
11504767
6.

Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.

Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M.

Cancer Res. 2001 Jul 15;61(14):5420-4.

7.

Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.

Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D.

Genet Epidemiol. 2001 Jul;21(1):1-18.

PMID:
11443730
8.

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73.

9.

A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.

Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3232-6.

10.

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA.

Am J Hum Genet. 2001 Mar;68(3):700-10.

11.

Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

Thompson D, Easton D; Breast Cancer Linkage Consortium..

Am J Hum Genet. 2001 Feb;68(2):410-9.

13.

Extension of the lod score: the mod score.

Clerget-Darpoux F.

Adv Genet. 2001;42:115-24. Review.

PMID:
11037317
14.

Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.

Syrjäkoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H.

J Natl Cancer Inst. 2000 Sep 20;92(18):1529-31. No abstract available.

PMID:
10995809
15.

Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.

Anton-Culver H, Cohen PF, Gildea ME, Ziogas A.

Eur J Cancer. 2000 Jun;36(10):1200-8.

PMID:
10882857
16.

Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.

Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, Toth J, Devilee P, King MC, Olah E.

Int J Cancer. 2000 Jun 1;86(5):737-40.

17.

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA.

Am J Hum Genet. 2000 Apr;66(4):1259-72.

18.

Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.

De Benedetti VM, Radice P, Pasini B, Stagi L, Pensotti V, Mondini P, Manoukian S, Conti A, Spatti G, Rilke F, Pierotti MA.

Hum Mutat. 1998;12(3):215.

PMID:
10660329
19.

Risk models for familial ovarian and breast cancer.

Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF.

Genet Epidemiol. 2000 Feb;18(2):173-90.

PMID:
10642429
20.

Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.

Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ.

Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):741-7.

Items per page

Supplemental Content

Support Center